SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

Treating Venous Thromboembolism with JETi™ Thrombectomy System

Clinical Outcomes For Acute Venous Thrombosis Treatment

Percutaneous thrombectomy for the treatment of venous thromboembolism

Percutaneous thrombectomy with the JETi™ Peripheral Thrombectomy System for the treatment of venous thrombosis

Overview: Retrospective Study

Cournoyer-Rodrigue et al., JVIR. 2019.

Background
Mechanical and pharmacomechanical based thrombectomy may improve clinical outcomes, reduce concomitant CDT and lessen need for intensive care unit stays compared to anticoagulation alone.

Objective
To evaluate the safety and efficacy of JETi™ Thrombectomy System in treating acute venous thrombosis.

Method
Retrospective evaluation of 18 consecutive patients with 21 instances of acute venous thrombosis in JETi™ Thrombectomy System new user facility.

Primary Endpoints
Technical Success Rate (restoration of antegrade flow with or without additional treatment of an underlying obstructive lesion) and Procedural Success Rate (technical success with or without the addition of overnight CDT).

Clinical Outcomes

The JETi™ Peripheral Thrombectomy System achieved a 100% procedural success rate in 18 consecutive patients with a wide variety of target treatment vessels and had ZERO reports of blood transfusions, hypotension or hemolysis..

 

 Procedural Success RateSingle-Session Clot ReductionOverall Clot Reduction
(Single-Session + Overnight CDT)
Iliofemoral Vein (n=9)100%81%96%
Axillosubclavian Vein (n=10)100%100%100%
Portal Vein (n=2)100%100%100%

 

*5 patients required overnight CDT.

JETi™ system achieved a 100% procedural success rate in a wide variety of target treatment vessels at a brand-new JETi™ user facility.

100%

JETi™ system can achieve successful venous thrombectomy without overnight catheter directed thrombolysis in most patients.

Success

Reducing the need for overnight thrombolytics can lessen utilization of hospital resources and decrease intensive care unit stays resulting in lower costs compared with CDT.

Lower cost

Reference:

Cournoyer-Rodrigue et al., JVIR. 2019.

MAT-2209359 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0